Genmab Announces Changes to its Executive Committee
Genmab A/S (Nasdaq: GMAB) announced changes to its Executive Committee to support its growth as a fully integrated biotech innovation powerhouse. Rayne Waller joins as Executive Vice President and Chief Technology Officer, while Brad Bailey is promoted to Executive Vice President and Chief Commercial Officer. Anthony Mancini, the current Executive Vice President and Chief Operating Officer, will leave Genmab.
Waller, with over 30 years of biopharmaceutical experience, will lead Genmab's technical operations, manufacturing, and supply chain capabilities. Bailey, previously Senior Vice President and US General Manager, will oversee global commercial strategies. Both will report directly to CEO Dr. Jan van de Winkel and join the existing Executive Committee members.
These changes aim to strengthen Genmab's commitment to its diverse mid- to late-stage clinical programs and pipeline, aligning with its 2030 vision to transform lives with innovative antibody medicines.
Genmab A/S (Nasdaq: GMAB) ha annunciato modifiche al suo Comitato Esecutivo per supportare la sua crescita come una potenza innovativa biotech completamente integrata. Rayne Waller entra come Vicepresidente Esecutivo e Chief Technology Officer, mentre Brad Bailey viene promosso a Vicepresidente Esecutivo e Chief Commercial Officer. Anthony Mancini, attuale Vicepresidente Esecutivo e Chief Operating Officer, lascerà Genmab.
Waller, con oltre 30 anni di esperienza nel settore biofarmaceutico, guiderà le operazioni tecniche, la produzione e le capacità della catena di approvvigionamento di Genmab. Bailey, precedentemente Vicepresidente Senior e Direttore Generale per gli Stati Uniti, si occuperà delle strategie commerciali globali. Entrambi riferiranno direttamente al CEO Dr. Jan van de Winkel e si uniranno ai membri esistenti del Comitato Esecutivo.
Queste modifiche mirano a rafforzare l'impegno di Genmab verso i suoi diversi programmi clinici in fase intermedia e avanzata e alla pipeline, allineandosi con la sua visione 2030 di trasformare le vite con farmaci ad anticorpi innovativi.
Genmab A/S (Nasdaq: GMAB) anunció cambios en su Comité Ejecutivo para respaldar su crecimiento como una potencia de innovación biotecnológica completamente integrada. Rayne Waller se une como Vicepresidente Ejecutivo y Chief Technology Officer, mientras que Brad Bailey es ascendido a Vicepresidente Ejecutivo y Chief Commercial Officer. Anthony Mancini, el actual Vicepresidente Ejecutivo y Chief Operating Officer, dejará Genmab.
Waller, con más de 30 años de experiencia en biofarmacéutica, liderará las operaciones técnicas, la manufactura y las capacidades de la cadena de suministro de Genmab. Bailey, anteriormente Vicepresidente Senior y Gerente General de EE.UU., supervisará las estrategias comerciales globales. Ambos reportarán directamente al CEO Dr. Jan van de Winkel y se unirán a los miembros existentes del Comité Ejecutivo.
Estos cambios tienen como objetivo fortalecer el compromiso de Genmab con sus diversos programas clínicos en etapas intermedias y avanzadas y la pipeline, alineándose con su visión 2030 de transformar vidas con medicamentos de anticuerpos innovadores.
Genmab A/S (Nasdaq: GMAB)는 완전 통합된 생명공학 혁신 강자로서의 성장을 지원하기 위해 이사회에 변화를 발표했습니다. Rayne Waller가 부사장 겸 최고 기술 책임자로 합류하며, Brad Bailey는 부사장 겸 최고 상업 책임자로 승진합니다. 현재 부사장 겸 최고 운영 책임자인 Anthony Mancini는 Genmab를 떠납니다.
Waller는 30년 이상의 생물의약품 경험을 바탕으로 Genmab의 기술 운영, 제조 및 공급망 능력을 이끌게 됩니다. 이전에 선임 부사장 겸 미국 총괄 매니저였던 Bailey는 전 세계 상업 전략을 감독합니다. 두 사람 모두 CEO Dr. Jan van de Winkel에게 직접 보고하며 기존 이사회 멤버가 됩니다.
이러한 변화는 Genmab의 다양한 중간 및 후기 단계 임상 프로그램과 파이프라인에 대한 헌신을 강화하고, 혁신적인 항체 의약품으로 삶을 변화시킬 2030 비전과 일치하는 것을 목표로 하고 있습니다.
Genmab A/S (Nasdaq: GMAB) a annoncé des changements au sein de son Comité Exécutif pour soutenir sa croissance en tant que puissance d'innovation biopharmaceutique entièrement intégrée. Rayne Waller rejoint en tant que Vice-Président Exécutif et Directeur Technique, tandis que Brad Bailey est promu Vice-Président Exécutif et Directeur Commercial. Anthony Mancini, l'actuel Vice-Président Exécutif et Directeur des Opérations, quittera Genmab.
Waller, avec plus de 30 ans d'expérience en bio-pharmaceutique, dirigera les opérations techniques, la production et les capacités de la chaîne d'approvisionnement de Genmab. Bailey, précédemment Vice-Président Sénior et Directeur Général pour les États-Unis, supervisera les stratégies commerciales mondiales. Tous deux rendront directement compte au PDG Dr. Jan van de Winkel et rejoindront les membres existants du Comité Exécutif.
Ces changements visent à renforcer l'engagement de Genmab envers ses divers programmes cliniques des stades intermédiaires et avancés et son pipeline, alignés avec sa vision 2030 de transformer des vies grâce à des médicaments anticorps innovants.
Genmab A/S (Nasdaq: GMAB) gab Änderungen im Vorstand bekannt, um das Wachstum als vollständig integriertes Biotechnologie-Innovationsunternehmen zu unterstützen. Rayne Waller wird Executive Vice President und Chief Technology Officer, während Brad Bailey zum Executive Vice President und Chief Commercial Officer befördert wird. Anthony Mancini, der derzeitige Executive Vice President und Chief Operating Officer, wird Genmab verlassen.
Waller, der über 30 Jahre Erfahrung in der Biopharmazie verfügt, wird die technischen Abläufe, die Produktion und die Lieferkettenfähigkeiten von Genmab leiten. Bailey, zuvor Senior Vice President und General Manager für die USA, wird die globalen Handelsstrategien überwachen. Beide werden direkt an den CEO Dr. Jan van de Winkel berichten und sich den bestehenden Mitgliedern des Vorstands anschließen.
Diese Änderungen zielen darauf ab, das Engagement von Genmab für seine vielfältigen klinischen Programme in der späten und mittleren Phase sowie für die Pipeline zu stärken, was mit der Vision 2030 übereinstimmt, Leben mit innovativen Antikörpermedikamenten zu transformieren.
- Appointment of experienced executives Rayne Waller and Brad Bailey to strengthen leadership team
- Restructuring of Executive Committee to support company growth and evolution
- Focus on enhancing technical operations and global commercial strategies
- Departure of Executive Vice President and Chief Operating Officer Anthony Mancini
- Rayne Waller joins as Executive Vice President and Chief Technology Officer
- Brad Bailey appointed as Executive Vice President and Chief Commercial Officer
- Anthony Mancini, Executive Vice President and Chief Operating Officer, will leave Genmab to pursue other opportunities
Rayne and Brad will report directly to Genmab’s President and CEO Dr. Jan van de Winkel and be based in
“I am deeply grateful to Anthony Mancini for his many contributions to Genmab during his tenure, and on behalf of the Board of Directors and the Executive Committee, I wish him continued success in his future endeavors,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “I’m also very pleased to welcome Rayne Waller and Brad Bailey to the Executive Committee as exceptionally talented leaders with expertise in their fields. These new additions strengthen our commitment to envision a bold future for our diverse and innovative mid- to late-stage clinical programs and pipeline that can impact the lives of as many patients as possible. I am confident in their ability to energize our teams and execute towards our 2030 vision to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines.”
Rayne will further solidify and strengthen Genmab’s technical operations capabilities and lead all the manufacturing and supply chain capabilities of Genmab’s proprietary programs through preclinical, clinical and commercial stages. Brad, who served Genmab as Senior Vice President and US General Manager, has been promoted to lead the direction, planning, and execution of Genmab’s global commercial strategies. He will continue as US General Manager on an interim basis.
Rayne brings more than 30 years of international biopharmaceutical experience, including CMC (chemistry, manufacturing and controls) operations, supply chain management, corporate governance, and oversight of multi-product, multi-ton production and multi-billion-dollar inventory management. Rayne was most recently Chief Operating Officer at Capsida Biotherapeutics, and he spent 27 years at Amgen, where he progressed through hands-on and strategic positions of increasing scope and responsibilities in product production, packaging, distribution, logistics, and plant and supply chain management.
Brad joined Genmab in 2020 as the company’s first General Manager in
About Genmab
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines.
Established in 1999, Genmab is headquartered in
This Media Release contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240816647609/en/
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
Source: Genmab A/S
FAQ
Who are the new executives joining Genmab's (GMAB) Executive Committee?
What is Rayne Waller's role at Genmab (GMAB)?
What is Brad Bailey's new position at Genmab (GMAB)?
Why is Genmab (GMAB) making changes to its Executive Committee?
